RE:Unsolicited takeover bid…The value would be very clear for a pharmaceutical corporation considering the dronabinol API and producer shortage, the move towards more shelf stable cheaper, natural cannabinoids when compared to the synthetic competitors, this also applies to CBD and the inevitability of the epidiolex generic and the demand that comes with it for CBD api, who else is licensed and capable of meeting such demand...let's not forget GW announced expansion for epidiolex production at an estimated 100m...despite patents for dronabinol/marinol/sativex, generics have been approved, same will happen with epidiolex only epidiolex revenue is 4x dronabinol...iv said this before...if jazz wants to protect its billion dollar baby they could add years to the monopoly and add capacity for North America by purchasing MPL...are they the bidder?...look at the landscape, MPL is years ahead..unsolicited takeover bid in progress IMO....considering the developments recently the time for this to happen is now.